Insulet Co. (NASDAQ:PODD – Get Rating) – Stock analysts at SVB Leerink dropped their Q4 2022 earnings estimates for shares of Insulet in a research note issued on Thursday, May 5th. SVB Leerink analyst D. Antalffy now expects that the medical instruments supplier will post earnings of $0.42 per share for the quarter, down from their prior forecast of $0.48. SVB Leerink also issued estimates for Insulet’s Q1 2023 earnings at $0.36 EPS, Q2 2023 earnings at $0.40 EPS, Q4 2023 earnings at $0.67 EPS and FY2023 earnings at $1.88 EPS.
Other equities research analysts have also recently issued research reports about the company. StockNews.com assumed coverage on Insulet in a report on Thursday, March 31st. They set a “hold” rating on the stock. Piper Sandler lowered their target price on Insulet from $295.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 24th. Robert W. Baird lowered their target price on Insulet from $315.00 to $275.00 in a report on Thursday, February 24th. Raymond James decreased their price objective on Insulet from $329.00 to $280.00 and set an “outperform” rating on the stock in a report on Thursday, February 24th. Finally, Bank of America assumed coverage on Insulet in a report on Wednesday, March 2nd. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $299.71.
Insulet (NASDAQ:PODD – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The medical instruments supplier reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.17. The business had revenue of $295.40 million for the quarter, compared to analysts’ expectations of $287.99 million. Insulet had a return on equity of 15.36% and a net margin of 3.91%. The company’s quarterly revenue was up 17.1% on a year-over-year basis.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Camden Capital LLC purchased a new position in Insulet during the 1st quarter worth approximately $252,000. Quadrant Capital Group LLC grew its holdings in shares of Insulet by 19.0% during the 1st quarter. Quadrant Capital Group LLC now owns 420 shares of the medical instruments supplier’s stock valued at $112,000 after acquiring an additional 67 shares in the last quarter. AIA Group Ltd grew its holdings in shares of Insulet by 190.3% during the 1st quarter. AIA Group Ltd now owns 3,678 shares of the medical instruments supplier’s stock valued at $980,000 after acquiring an additional 2,411 shares in the last quarter. CIBC Asset Management Inc grew its holdings in shares of Insulet by 109.8% during the 1st quarter. CIBC Asset Management Inc now owns 6,671 shares of the medical instruments supplier’s stock valued at $1,777,000 after acquiring an additional 3,491 shares in the last quarter. Finally, IFM Investors Pty Ltd grew its holdings in shares of Insulet by 21.1% during the 1st quarter. IFM Investors Pty Ltd now owns 10,416 shares of the medical instruments supplier’s stock valued at $2,775,000 after acquiring an additional 1,817 shares in the last quarter.
In other Insulet news, CFO Wayde D. Mcmillan sold 1,455 shares of Insulet stock in a transaction that occurred on Friday, April 1st. The shares were sold at an average price of $275.60, for a total transaction of $400,998.00. Following the transaction, the chief financial officer now directly owns 21,354 shares in the company, valued at approximately $5,885,162.40. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Shacey Petrovic sold 15,000 shares of Insulet stock in a transaction that occurred on Monday, April 4th. The stock was sold at an average price of $273.25, for a total transaction of $4,098,750.00. Following the transaction, the chief executive officer now owns 13,607 shares in the company, valued at $3,718,112.75. The disclosure for this sale can be found here. 0.90% of the stock is currently owned by company insiders.
About Insulet (Get Rating)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.
- Get a free copy of the StockNews.com research report on Insulet (PODD)
- Nasdaq Stock is a Buy the (Deep) Dip Opportunity
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.